Meeting
2011 ASCO Annual Meeting
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
X. Huang
Medical Oncology Branch, National Cancer Institute, Bethesda, MD
X. Huang , Y. M. Ning , M. Mulquin , R. A. Madan , J. L. Gulley , P. G. Kluetz , D. Adelberg , P. M. Arlen , H. L. Parnes , B. Adesunloye , S. M. Steinberg , J. J. Wright , J. B. Trepel , C. Chen , C. Bassim , A. B. Apolo , W. D. Figg , W. L. Dahut
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00942578
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4574)
Abstract #
4574
Poster Bd #
1D
Abstract Disclosures
Similar Posters
Poster
2011 Genitourinary Cancers Symposium
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Xuan Huang
Poster
2012 ASCO Annual Meeting
Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Bamidele Adesunloye
Poster
2014 ASCO Annual Meeting
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).
First Author: Daniel Louis Hertz
Poster
2013 Genitourinary Cancers Symposium
Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.
First Author: Fatima H. Karzai